ADAG
Adagene Inc - ADR

220
Mkt Cap
$92.38M
Volume
4,975.00
52W High
$3.16
52W Low
$1.30
PE Ratio
-3.04
ADAG Fundamentals
Price
$1.90
Prev Close
$1.96
Open
$1.90
50D MA
$1.81
Beta
0.07
Avg. Volume
52,441.82
EPS (Annual)
-$0.7426
P/B
2.44
Rev/Employee
$748.23
Loading...
Loading...
News
all
press releases
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 48.9%
Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 23,778 shares, a...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat...
MarketBeat·16d ago
News Placeholder
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Declines By 36.8%
Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest...
MarketBeat·23d ago
News Placeholder
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
Zacks·1mo ago
News Placeholder
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat.com...
MarketBeat·1mo ago
News Placeholder
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Average Recommendation of "Moderate Buy" from Brokerages
Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports. One research...
MarketBeat·2mo ago
News Placeholder
Adagene (NASDAQ:ADAG) Upgraded to Strong-Buy at Lifesci Capital
Lifesci Capital raised shares of Adagene to a "strong-buy" rating in a research report on Friday...
MarketBeat·2mo ago
News Placeholder
Adagene (NASDAQ:ADAG) Trading 4.1% Higher - Time to Buy?
Adagene (NASDAQ:ADAG) Shares Up 4.1% - Here's What Happened...
MarketBeat·2mo ago
News Placeholder
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·4mo ago
News Placeholder
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks·4mo ago
<
1
2
...
>

Latest ADAG News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.